These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18080768)

  • 41. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease.
    Vespasiani Gentilucci U; Caviglia R; Picardi A; Carotti S; Ribolsi M; Galati G; Petitti T; Afeltra A; Cicala M
    Aliment Pharmacol Ther; 2005 May; 21(9):1063-71. PubMed ID: 15854167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls.
    Geerling BJ; Badart-Smook A; Stockbrügger RW; Brummer RJ
    Eur J Clin Nutr; 2000 Jun; 54(6):514-21. PubMed ID: 10878655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential behavior of coagulation factor XIII in patients with inflammatory bowel disease and in patients with giant cell arteritis.
    Vrij AA; Rijken J; van Wersch JW; Stockbrügger RW
    Haemostasis; 1999; 29(6):326-35. PubMed ID: 10844406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Body Composition in Crohn's Disease and Ulcerative Colitis: Correlation with Disease Severity and Duration.
    Yadav DP; Kedia S; Madhusudhan KS; Bopanna S; Goyal S; Jain S; Vikram NK; Sharma R; Makharia GK; Ahuja V
    Can J Gastroenterol Hepatol; 2017; 2017():1215035. PubMed ID: 29226115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma transforming growth factor-beta1 level in inflammatory bowel disease.
    Kiliç ZM; Ayaz S; Ozin Y; Nadir I; Cakal B; Ulker A
    Turk J Gastroenterol; 2009 Sep; 20(3):165-70. PubMed ID: 19821197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.
    Owczarek D; Undas A; Foley JH; Nesheim ME; Jabłonski K; Mach T
    J Crohns Colitis; 2012 Feb; 6(1):13-20. PubMed ID: 22261523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease.
    Holtkamp W; Stollberg T; Reis HE
    J Clin Gastroenterol; 1995 Mar; 20(2):123-6. PubMed ID: 7769191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro Benallal D; Benítez Roldán A; Merino V; Ramirez G; Calleja-Hernández MA; Caunedo Álvarez A; Romero Gómez M
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlations of plasma citrulline levels with clinical and endoscopic score and blood markers according to small bowel involvement in pediatric Crohn disease.
    Lee EH; Ko JS; Seo JK
    J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):570-5. PubMed ID: 23752073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease.
    Yılmaz B; Köklü S; Yüksel O; Arslan S
    World J Gastroenterol; 2014 Aug; 20(31):10916-20. PubMed ID: 25152594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of long-lasting nutritional prehabilitation on postoperative outcome in elective surgery for IBD.
    Fiorindi C; Cuffaro F; Piemonte G; Cricchio M; Addasi R; Dragoni G; Scaringi S; Nannoni A; Ficari F; Giudici F
    Clin Nutr; 2021 Mar; 40(3):928-935. PubMed ID: 32684485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease.
    Shentova R; Baycheva M; Kofinova D; Hadjiiski P; Yaneva P
    Folia Med (Plovdiv); 2020 Jun; 62(2):271-275. PubMed ID: 32666743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
    Herrlinger KR; Diculescu M; Fellermann K; Hartmann H; Howaldt S; Nikolov R; Petrov A; Reindl W; Otte JM; Stoynov S; Strauch U; Sturm A; Voiosu R; Ammendola A; Dietrich B; Hentsch B; Stange EF
    J Crohns Colitis; 2013 Sep; 7(8):636-43. PubMed ID: 23078909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use.
    Subramanian S; Asher R; Weston W; Rimmer M; McConville A; Malin A; Jackson R; Collins P; Probert C; Dibb M; Rhodes JM
    Inflamm Bowel Dis; 2016 Aug; 22(8):1902-7. PubMed ID: 27243590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn's Disease.
    Kim SH; Jang SH; Kim JW; Kim BG; Lee KL; Kim YS; Han DS; Kim JS
    Am J Med Sci; 2017 May; 353(5):439-444. PubMed ID: 28502329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
    Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
    World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease.
    Caliskan Z; Gokturk HS; Caliskan M; Gullu H; Ciftci O; Ozgur GT; Guven A; Selcuk H
    Microvasc Res; 2015 Jan; 97():25-30. PubMed ID: 25128749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Could platelet indices be new biomarkers for inflammatory bowel diseases?
    Öztürk ZA; Dag MS; Kuyumcu ME; Cam H; Yesil Y; Yilmaz N; Aydinli M; Kadayifci A; Kepekci Y
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):334-41. PubMed ID: 23426536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.